Be sure to join Dr. Singer today for an important presentation about the impact that the COVID-19 pandemic has had on NCI and the extramural community. She will give an overview of NCI’s efforts to contribute to the COVID-19 crisis by pivoting some cancer research activities to focus on SARS-CoV-2 as well as highlight examples of how NCI continues to make progress in cancer research. Dr. Singer will also be providing some details on how NCI, working with NIH, has implemented new flexibilities for the cancer research community during this crisis.
Some of these flexibilities include:
- Extended deadlines for applications
- Use of NCI grant funds for salaries and stipends
- Flexibility on extensions of projects and reporting requirements
- Extensions for early stage investigators and trainees.
Tune in today at 5:20 PM EDT
Registration is free and open to the public.
A comprehensive list of COVID-related resources from NCI is available at Coronavirus: Guidance for Cancer Researchers.
|
Translational Prevention Studies
10:45 a.m. - 12:30 p.m. | NCI Participants: Eva Szabo (Chairperson), Altaf Mohammed, Shizuko Sei, Robert Shoemaker, Mark Miller
This minisymposium presents a multidisciplinary program of state-of-the-art laboratory, clinical, and translational research addressing multiple aspects of prevention research. Abstracts describing epidemiologic studies, animal model development, biomarker identification, and chemoprevention studies will be presented.
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL
10:45 a.m. - 1:20 p.m. | NCI Participants: Haneen Shalabi, Bonnie Yates, Shilpa Shahani, Haiying Qin, Leah Hoffman, Lauren Little, Katherine Graap, Nirali N. Shah
Learn how this trial tested novel, humanized bispecific CD19/CD22 CAR T cells, developed to overcome resistance with approved CAR T-cell therapies, in patients with relapsed/refractory acute B-cell lymphoblastic leukemia. Eight of 11 patients who received the treatment had objective responses, with four minimal residual disease (MRD)-negative complete responses and four partial responses. The treatment was well tolerated, with best responses in patients who did not receive prior CAR T-cell therapy.
Novel Targets and Therapies
2:15 - 3:45 p.m. | NCI Participant: Naoko Takebe (Chairperson)
This session will showcase the identification of new drug targets using small molecules and the exploration of novel cell surface receptor using a proprietary chemotherapy delivery platform.
A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study
2:25 - 2:35 p.m. | NCI Participants: Elad Sharon, Helen Chen
Join this presentation to learn more about a randomized trial of atezolizumab versus atezolizumab and cobimetinib in patients with cholangiocarcinoma. This trial is based on preclinical data suggesting that MEK inhibition may potentiate the efficacy of immunotherapy. The trial demonstrated a modest but statistically significant increase in the progression free survival on the combination arm. Correlative studies are underway and may provide guidance for development of this or other combination regimens for patients afflicted by this horrible disease.
Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project
4:55 - 5:05 p.m. | NCI Participants: Laura M. Yee, Mickey Williams, Lisa McShane
As more gene panel-based assays are developed to estimate tumor mutation burden (TMB), harmonization is emerging as an unmet need and is a key goal of the Friends of Cancer Research TMB Harmonization Project. The investigators report on Phase 2B of their study, which aims to characterize variability in TMB measurements in clinical samples and to establish best practices for estimating and aligning TMB in order to improve consistency across panels.
Oncologic therapy shapes the fitness landscape of clonal hematopoiesis
4:10 - 4:20 p.m. | NCI Participants: Choonsik Lee, Montserrat Garcia-Closas, Lindsay Morton
Utilizing targeted, deep coverage next-generation sequencing data (MSK-IMPACT) to identify clonal hematopoiesis-related mutations, we show that patients previously treated with oncologic therapy have increased rates of clonal hematopoiesis, with increased mutation frequency in DNA damage response-related genes. Improved understanding of clonal hematopoiesis-related mutational features could impact clinical practice for early detection and treatment decisions in patients at high risk of progressing to therapy-related myeloid neoplasia.
A standard operating procedure for the interpretation of oncogenicity/pathogenicity of somatic mutations
5:05 - 5:15 p.m. | NCI Participant: Dmitriy Sonkin
Join to learn about the development of the SOP for the interpretation of oncogenicity of somatic mutations. The discussion will include the rationale, intended scope and key features of the SOP.
Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A
4:05 - 4:15 p.m. | NCI Participants: James Zwiebel, Lisa McShane, Lyndsay Harris, Helen Chen, Mickey Williams, Barbara Conley, Alice Chen, Larry Rubinstein
Preclinical and clinical data have suggested that downstream inhibition with a MEK inhibitor, such as binimetinib, might be efficacious for NRAS-mutated cancers. In the NCI-MATCH Precision Medicine study, Z1A patients with refractory solid tumors harboring codon 12, 13, or 61 NRAS-mutations were enrolled on a single arm study of binimetinib 45 mg twice daily. While the trial did not meet the primary endpoint (RR=2.1%), it was noted that patients whose tumors harbored the codon 61 mutation had a significantly longer OS (p=0.04) and PFS (p=0.006) than those with tumors harboring codon 12 or 13 NRAS-mutations. Further study of binimetinib in tumors with codon 61 mutations may be warranted.
Please join us this summer for AACR Virtual Annual Meeting II (June 22-24). AACR will release registration information soon. The titles and abstracts of presentations in AACR Virtual Annual Meeting II will be posted online on Friday, May 15.
For more information about NCI's presentations at AACR's meeting, visit us at https://www.cancer.gov/news-events/events/conferences/aacr-2020
|
|
